secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001193125-23-089530
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion prices upsized $150M public offering of 5M shares at $30; net proceeds ~$161.6M
--------------------------------------------------------------------------------

- Offering of 5,000,000 shares at $30.00 per share; gross proceeds of $150.0 million.
- Underwriters exercised 30-day option to purchase additional 750,000 shares in full.
- Net proceeds of approximately $161.6 million after underwriting discounts and expenses.
- Proceeds to fund clinical development of BMF-219 (menin inhibitor) and BMF-500 (FLT3 inhibitor).
- J.P. Morgan and Citigroup acted as joint book-running managers; closing on April 3, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523089530/0001193125-23-089530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312523089530/d486927d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-089530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer